Unlock instant, AI-driven research and patent intelligence for your innovation.

CA-4P containing pharmaceutical composition, preparation method of CA-4P containing pharmaceutical composition, and application to vascular interventional therapy of liver cancer

A technology of CA-4P and CA-4P1, which is applied to the pharmaceutical composition containing CA-4P and its preparation, and the application field of vascular interventional therapy for liver cancer, which can solve the problem of limited application, human toxic and side effects, and the absence of CA-4P and other problems, to achieve the effect of less toxic and side effects, simple operation and remarkable curative effect

Inactive Publication Date: 2018-10-02
ZHEJIANG DADE PHARMACEUTICAL GROUP CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] However, like most chemotherapeutic drugs, because CA-4P has great toxic and side effects on the human body, especially cardiotoxicity, which limits its clinical application, CA-4P has not been found in the prior art for vascular intervention in liver cancer. treat

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CA-4P containing pharmaceutical composition, preparation method of CA-4P containing pharmaceutical composition, and application to vascular interventional therapy of liver cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Example 1: A pharmaceutical composition containing CA-4P, calculated in parts by weight, including 1 part of CA-4P and 5 parts of mannitol.

[0044] The pharmaceutical composition containing CA-4P is a powder injection.

[0045] The preparation method of the pharmaceutical composition powder injection containing CA-4P is prepared according to the following steps under dark conditions:

[0046]a. According to the total amount of 2000ml solution, weigh 10gCA-4P and 100g mannitol, add water for injection to 1600ml, stir until completely dissolved, and obtain product A;

[0047] b. Add 1.6g of activated carbon for needles into product A, stir evenly, let stand for 10 minutes, filter through a 0.45μm microporous membrane, add water for injection to 2000ml, and obtain product B;

[0048] c. Adjust the pH of product B to 7.8 to obtain product C;

[0049] d. Filter product C through a 0.22 μm microporous membrane to obtain product D;

[0050] e. Quantitative filling of produ...

Embodiment 2

[0056] Example 2: A pharmaceutical composition containing CA-4P, calculated in parts by weight, including 1 part of CA-4P and 10 parts of mannitol.

[0057] The pharmaceutical composition containing CA-4P is a powder injection.

[0058] The preparation method of the pharmaceutical composition powder injection containing CA-4P is prepared according to the following steps under dark conditions:

[0059] a. According to the total amount of 2500ml solution, weigh 25gCA-4P and 125g mannitol, add water for injection to 2000ml, stir until completely dissolved, and obtain product A;

[0060] b. Add 2.5g of activated carbon for needles into product A, stir evenly, let stand for 10 minutes, filter through a 0.45μm microporous membrane, add water for injection to 2500ml, and obtain product B;

[0061] c. Adjust the pH of product B to 7.8 to obtain product C;

[0062] d. Filter product C through a 0.22 μm microporous membrane to obtain product D;

[0063] e. Quantitative filling of pro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a CA-4P containing pharmaceutical composition, a preparation method of the CA-4P containing pharmaceutical composition, and an application of the CA-4P containing pharmaceutical composition to the vascular interventional therapy of the liver cancer. The CA-4P containing pharmaceutical composition comprises 1 part by weight of CA-4P and 5-10 parts by weight of mannitol. A finished product is obtained by completely dissolving the CA-4P and the mannitol with water for injection under the dark condition, adding syringe-use activated carbon, stirring evenly, allowing standing still, filtering by using a 0.45 [mu]m microfiltration membrane, additionally adding water for injection, then filtering by using a 0.22 [mu]m microfiltration membrane, measuring the pH value, quantitively filling, freeze-drying, charging nitrogen, pressing a plunger, pressing an aluminum cover, pasting a label, packaging, and sampling until the qualified standard is reached. The CA-4P is takenas the raw material to manufacture the CA-4P containing pharmaceutical composition, and the CA-4P containing pharmaceutical composition is applied to the vascular interventional therapy of the liver cancer. The application of the CA-4P containing pharmaceutical composition has the advantages of safety, reliability, obvious treatment effect, and low toxic and side effects.

Description

technical field [0001] The invention relates to the technical field of chemical drugs, in particular to a pharmaceutical composition containing CA-4P, a preparation method thereof and an application in vascular interventional therapy of liver cancer. Background technique [0002] Liver cancer refers to malignant tumors that occur in the liver, including primary liver cancer and secondary liver cancer. It is one of the most common malignant tumors in my country. Vascular interventional therapy for liver cancer refers to a regional local treatment in which chemotherapeutic drugs or embolic agents are injected into the hepatic artery through arterial catheterization. It is currently the most commonly used method for clinical treatment of primary liver cancer. The main physiological basis of vascular interventional therapy is that 20%-25% of the blood supply of normal liver cells comes from the hepatic artery, and 75%-85% comes from the portal vein. However, 90%-95% of the bloo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/661A61K9/19A61K47/26A61P1/16A61P35/00
CPCA61K31/661A61K9/19A61K47/26A61P1/16A61P35/00
Inventor 王建平王建国
Owner ZHEJIANG DADE PHARMACEUTICAL GROUP CO LTD